Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167362 · ClinicalTrials.gov registry record · Phase 3
Cognitive Enhancement Therapy for Early-Stage Schizophrenia
A Phase 3 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
NCT00167362: Completed Phase 3 study, sponsored by Beth Israel Deaconess Medical Center.
NCT00167362 is a Phase 3 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 67 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00167362, a Phase 3 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of cognitive enhancement therapy (CET) in treating cognitive abnormalities in people experiencing the early stages of schizophrenia.
Interventions
- BEHAVIORAL Cognitive enhancement therapy (CET)
- BEHAVIORAL Enriched supportive therapy (EST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2001-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT00167362 record still lists
NCT00167362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Cognitive enhancement therapy (CET) is the first listed.
NCT00167362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00167362 about?
NCT00167362 is a clinical study titled "Cognitive Enhancement Therapy for Early-Stage Schizophrenia". This study will determine the effectiveness of cognitive enhancement therapy (CET) in treating cognitive abnormalities in people experiencing the early stages of schizophrenia.
What is the current status of trial NCT00167362?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2001-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00167362?
The interventions under investigation include: Cognitive enhancement therapy (CET) (BEHAVIORAL), Enriched supportive therapy (EST) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00167362?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00167362's enrollment target sits among peer trials
67 1796th of 2000 higher than 204 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia